{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:08:34Z","timestamp":1775488114866,"version":"3.50.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,3]]},"abstract":"<jats:p>\n                    Gastric cancer continues to be a worldwide health crisis because it results in many deaths. The protein Claudin 18.2 (CLDN18.2) exists at higher levels in gastric adenocarcinoma tumors which makes it a promising therapeutic target. This study evaluated CLDN18.2 protein levels in gastric cancer tissues and their relationship with patient and tumor characteristics. This retrospective cohort study analyzed 112 gastric adenocarcinoma patients together with 62 healthy controls. The research team used ELISA to determine CLDN18.2 concentrations in tumor tissue and adjacent normal tissue and control specimens. Patients were stratified based on their Helicobacter\n                    <jats:italic toggle=\"yes\">pylori<\/jats:italic>\n                    infection status, tumor site, tumor grade, and presence of metastasis. Diagnostic performance was assessed using receiver operating characteristic analysis, and Cox regression analysis was performed to evaluate prognostic factors for survival. The cancer tissue contained elevated CLDN18.2 levels which measured at 2.385\u2009ng\/mL (median), whereas normal tissue and controls displayed 1.349\u2009ng\/mL and 1.260\u2009ng\/mL (median) respectively (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). The receiver operating characteristic analysis for diagnosing gastric adenocarcinoma showed 92.4% sensitivity and 100% specificity at 1.675\u2009ng\/mL (area under the curve: 0.956). The study found that CLDN18.2 levels were higher in patients with Helicobacter\n                    <jats:italic toggle=\"yes\">pylori<\/jats:italic>\n                    infection and in cases with poor tumor differentiation and metastasis. The risk of metastasis increased by 4.82 times for every 1\u2009ng\/mL rise in CLDN18.2 levels (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). This study demonstrates that CLDN18.2 exhibits strong diagnostic performance for gastric adenocarcinoma and shows strong correlation with cancer progression. The Cox regression analysis established CLDN18.2 as an independent prognostic factor for patient survival outcomes.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000048192","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:00:41Z","timestamp":1775232041000},"page":"e48192","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Tissue Claudin 18.2 levels as a prognostic factor in gastric adenocarcinomas: A retrospective cohort study"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3486-1787","authenticated-orcid":false,"given":"Enver","family":"Akbas","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6zde","family":"\u00dclfer","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260406","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-017-0473-4","article-title":"Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer.","volume":"10","author":"Singh","year":"2017","journal-title":"J. Hematol. Oncol"},{"key":"R2-20260406","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3748\/wjg.v28.i12.1187","article-title":"Epidemiology of stomach cancer.","volume":"28","author":"Ilic","year":"2022","journal-title":"World J Gastroenterol"},{"key":"R3-20260406","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/cancers16030679","article-title":"Claudin 18.2 as a new biomarker in gastric cancer\u2014what should we know?","volume":"16","author":"Mathias-Machado","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R4-20260406","doi-asserted-by":"crossref","first-page":"100762","DOI":"10.1016\/j.esmoop.2022.100762","article-title":"Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer.","volume":"8","author":"Kubota","year":"2023","journal-title":"ESMO Open"},{"key":"R5-20260406","first-page":"212","article-title":"Advances and challenges in gastric cancer testing: the role of biomarkers.","volume":"22","author":"Sun","year":"2025","journal-title":"Cancer Biol Med"},{"key":"R6-20260406","doi-asserted-by":"crossref","first-page":"49565","DOI":"10.18632\/oncotarget.10391","article-title":"Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer.","volume":"7","author":"Liang","year":"2016","journal-title":"Oncotarget"},{"key":"R7-20260406","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1007\/s12094-025-03865-6","article-title":"Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).","volume":"27","author":"Alsina Maqueda","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"R8-20260406","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-022-00385-1","article-title":"Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy.","volume":"10","author":"Cao","year":"2022","journal-title":"Biomarker Res"},{"key":"R9-20260406","doi-asserted-by":"crossref","first-page":"1967080","DOI":"10.1080\/21688370.2021.1967080","article-title":"Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials.","volume":"10","author":"Kyuno","year":"2022","journal-title":"Tissue barriers"},{"key":"R10-20260406","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/cancers14020290","article-title":"Claudins and gastric cancer: an overview.","volume":"14","author":"Hashimoto","year":"2022","journal-title":"Cancers"},{"key":"R11-20260406","doi-asserted-by":"crossref","first-page":"643872","DOI":"10.3389\/fonc.2021.643872","article-title":"Clinicopathologic relevance of claudin 18.2 expression in gastric cancer: a meta-analysis.","volume":"11","author":"Ungureanu","year":"2021","journal-title":"Front Oncol"},{"key":"R13-20260406","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system.","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"R14-20260406","doi-asserted-by":"crossref","first-page":"102269","DOI":"10.1101\/pdb.prot102269","article-title":"Bradford assay for determining protein concentration.","volume":"2020","author":"Kielkopf","year":"2020","journal-title":"Cold Spring Harbor protocols"},{"key":"R15-20260406","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences.","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"R16-20260406","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/cncy.22688","article-title":"Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: a comparative study with tissue specimens.","volume":"131","author":"Dai","year":"2023","journal-title":"Cancer Cytopathol"},{"key":"R17-20260406","doi-asserted-by":"crossref","first-page":"e2261","DOI":"10.1002\/hsr2.2261","article-title":"Potential diagnostic, prognostic, and predictive biomarkers of gastric cancer.","volume":"7","author":"Mohammed","year":"2024","journal-title":"Health Sci Rep"},{"key":"R18-20260406","doi-asserted-by":"crossref","first-page":"78","DOI":"10.21147\/j.issn.1000-9604.2024.01.08","article-title":"Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: a retrospective study.","volume":"36","author":"Qi","year":"2024","journal-title":"Chin J Cancer Res"},{"key":"R19-20260406","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3390\/cancers17132120","article-title":"Correlation of CLDN18.2 and tumor microenvironment in gastric cancer: a systematic review.","volume":"17","author":"Zarampouka","year":"2025","journal-title":"Cancers"},{"key":"R20-20260406","doi-asserted-by":"crossref","first-page":"20047","DOI":"10.1038\/s41598-023-47178-6","article-title":"Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer.","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"R21-20260406","doi-asserted-by":"crossref","first-page":"17648","DOI":"10.1038\/s41598-024-68411-w","article-title":"Heterogeneity of claudin 18.2 expression in metastatic gastric cancer.","volume":"14","author":"Choi","year":"2024","journal-title":"Sci Rep"},{"key":"R22-20260406","doi-asserted-by":"crossref","first-page":"100569","DOI":"10.1016\/j.modpat.2024.100569","article-title":"The clinicopathological and molecular characteristics of endocervical gastric-type adenocarcinoma and the use of claudin18.2 as a potential therapeutic target.","volume":"37","author":"Yang","year":"2024","journal-title":"Modern Pathol"},{"key":"R23-20260406","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.21037\/jgo-22-462","article-title":"Decreased expression of claudin-18.2 in alpha-fetoprotein-producing gastric cancer compared to conventional gastric cancer.","volume":"13","author":"Weng","year":"2022","journal-title":"J Gastrointestinal Oncol"},{"key":"R24-20260406","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5230\/jgc.2025.25.e2","article-title":"Discordance in claudin 18.2 expression between primary and metastatic lesions in patients with gastric cancer.","volume":"25","author":"Son","year":"2025","journal-title":"J Gastric Cancer"},{"key":"R25-20260406","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3748\/wjg.v28.i4.402","article-title":"Helicobacter pylori infection: How does age influence the inflammatory pattern?","volume":"28","author":"Ara\u00fajo","year":"2022","journal-title":"World J Gastroenterol"},{"key":"R26-20260406","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/jpm11111095","article-title":"Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas.","volume":"11","author":"Pellino","year":"2021","journal-title":"J Personalized Med"},{"key":"R27-20260406","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4251\/wjgo.v15.i2.343","article-title":"Prognostic value of claudin 18.2 expression in gastric adenocarcinoma.","volume":"15","author":"Kayikcioglu","year":"2023","journal-title":"World J Gastrointestinal Oncol"},{"key":"R28-20260406","doi-asserted-by":"crossref","first-page":"559","DOI":"10.5858\/arpa.2021-0428-OA","article-title":"Claudin-18: patterns of expression in the upper gastrointestinal tract and utility as a marker of gastric origin in neuroendocrine tumors.","volume":"147","author":"Wong","year":"2022","journal-title":"Arch Pathol Laboratory Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:01:31Z","timestamp":1775484091000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":27,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048192","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"2025-11-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}